Medicines shortages are a significant cause of concern for patients, clinicians and our public health. They impact on patients’ health outcomes by causing delays in treatment or forcing changes in treatment regimes, as well as inducing a great deal of stress and worry to patients and their families, states a website posting by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
The European associations representing manufacturers of vaccines and medicines, parallel distributors, pharmaceutical full-line wholesalers and industrial pharmacists are committed to working with the European Union and member states to progress short term and longer term solutions addressing the root causes of medicines shortages that occur across Europe.
The root causes of medicines shortages include manufacturing, quality, economic, and supply chain issues. The associations are committed to stepping up efforts to prevent and to mitigate medicines shortages. As a group, they believe that the root causes of shortages can be addressed by a set of short term and longer term solutions including harmonizing data and monitoring medicines shortages at EU level, creating regulatory incentives for essential low-priced medicines, allowing regulatory flexibility and improved regulatory efficiency to mitigate shortages, and ensuring market stability and sustainability.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze